Compare TLIH & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TLIH | PHIO |
|---|---|---|
| Founded | 1998 | 2011 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.8M | 12.3M |
| IPO Year | 2025 | N/A |
| Metric | TLIH | PHIO |
|---|---|---|
| Price | $0.41 | $1.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $10.67 |
| AVG Volume (30 Days) | ★ 396.2K | 360.2K |
| Earning Date | 09-30-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $51,204,304.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.94 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.31 | $0.97 |
| 52 Week High | $7.00 | $9.79 |
| Indicator | TLIH | PHIO |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 34.21 |
| Support Level | N/A | $1.04 |
| Resistance Level | N/A | $1.20 |
| Average True Range (ATR) | 0.00 | 0.09 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 0.00 | 15.53 |
Ten-League International Holdings Ltd is a Singapore-based provider of turnkey project solutions. Its business consists of sales of heavy equipment and parts, heavy equipment rental and provision of engineering consultancy services to port, construction, civil engineering and underground foundation industries. It currently conducts its operations through its wholly-owned subsidiaries. The equipment it provides is organized into four categories based on their functions and application scenarios, namely, foundation equipment, hoist equipment, excavation equipment and port machinery. The company operates in Singapore and Other International Countries.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.